Univo IRB Launches First-of-Its-Kind Electronic IRB Submission Portal, OneVerse™

RALEIGH, N.C.; June 26, 2024 (Business Wire) – Univo IRB, a next generation institutional review board (IRB), announced the launch of OneVerseTM — the industry’s first purpose-built, electronic platform that modernizes the IRB experience. OneVerse is designed around user experience and transparency, facilitating seamless study submission, secure document sharing, and direct communication across all research study stakeholders.


“Univo IRB team members have worked on all sides of clinical research,” said Heather Fitzgerald, Univo IRB’s VP of Operations. “We’ve witnessed IRB technology slowing down the review processes with lengthy forms, limited transparency, and poor communication. We took our firsthand experience and designed a modern and user-friendly platform. OneVerse will completely change how users think about IRB submission and allow research organizations, sites, and sponsors to get to study startup faster.”


OneVerse was developed with industry expertise in artificial intelligence (AI) combined with a user centric design process. “When combined with Univo’s extensive IRB operational and regulatory expertise, OneVerse changes the way customers and patients will engage with an IRB,” said Julie Blasingim, Univo IRB’s CEO. “Univo’s focus on enabling highly efficient IRB processes and connecting patients with researchers drove our system design to streamline submissions and foster transparency, benefiting multiple research stakeholders.”


OneVerse features include the ability for users to access a searchable review of submission statuses and action items; dynamic generation of processes, forms, and requests; simple collaboration allowing study teams to access documentation, amendments, and updates; and tailored submission guidance and IRB resources available 24/7. Compared to other IRB tools and processes, the platform creates many efficiencies by using AI to automate administrative tasks as part of an overall enhanced end user experience. New functionality will continue to be released throughout 2024 helping to establish OneVerse as the new standard in IRB innovation technology.


Visit Univo-Group.com/OneVerse for more information or to request a demo.


About Univo IRB 
Univo IRB, formerly Principal IRB, is a next generation institutional review board (IRB) specializing in the ethical review of Phase I-IV pharmaceutical, device, biologic, behavioral, and psycho-social research. We offer agile study approaches, expert solutions powered by industry-leading study technology, and a service-first approach. Univo IRB holds accreditation through the Association for the Accreditation of Human Research Protection Programs (AAHRPP). With support from senior advisors and 60+ years of industry experience, Univo IRB guides studies to approval while respecting the rights and welfare of patients every step of the way.